Search - tctmd.com

Displaying 161 - 180 of 1583

Sort: Relevancy | Date

Deprescribing Antihypertensives May Slow Cognitive Decline in Nursing Home Patients

News Daily News

Deprescribing Antihypertensives May Slow Cognitive Decline in Nursing Home Patients

September 27, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

Liraglutide Helps Shed Weight in Young Children With Obesity

News Daily News

Liraglutide Helps Shed Weight in Young Children With Obesity

September 13, 2024

Hypertension Control in the US Still Has a Long Way to Go

News Daily News

Hypertension Control in the US Still Has a Long Way to Go

September 12, 2024

Statins Are Cost-effective in the Elderly

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

September 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

September 01, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

BedMed and BedMed-Frail randomized controlled trials

Presentation ESC 2024

BedMed and BedMed-Frail randomized controlled trials

Presenter: Scott Garrison

August 31, 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

Continuation versus Interruption of Oral Anticoagulation during TAVI

Presentation ESC 2024

Continuation versus Interruption of Oral Anticoagulation during TAVI

Presenter: Dirk-Jan van Ginkel

August 31, 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

August 31, 2024

Good News for CV Recovery After COVID-19 Vaccine Myocarditis

News Daily News

Good News for CV Recovery After COVID-19 Vaccine Myocarditis

Yael L. Maxwell

August 29, 2024

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

News Daily News

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

August 28, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.